Neurotrophic delivery in Alzheimer’s-model mice by Elisa Konofagou et al.
ORAL PRESENTATION Open Access
Neurotrophic delivery in Alzheimer’s-model mice
Elisa Konofagou*, Hong Chen, Oluyemi Olumolade, Karen Duff
From Current and Future Applications of Focused Ultrasound 2014. 4th International Symposium
Washington, D.C, USA. 12-16 October 2014
Background/introduction
Alzheimer’s disease (AD), which has emerged as one of
the most common brain disorders, begins in the hippo-
campal formation and gradually spreads to the remaining
brain at its most advanced stages, and is characterized
partly by deposition of amyloid plaques in the brain tissue
but also in the blood vessels themselves. Our studies have
dealt with both the delivery of neurotrophic factors
through the FUS-induced blood-brain barrier (BBB) open-
ing to the hippocampus in both the presence and absence
of disease in AD mouse models. The Brain-Derived Neu-
rotrophic Factor (BDNF) is widely and abundantly
expressed in the CNS and is available to some peripheral
nervous system neurons that uptake the neurotrophin pro-
duced by peripheral tissues. BDNF can modulate neuronal
synaptic strength and has been implicated in hippocampal
mechanisms of learning and memory. As BDNF has been
proven to serve as a neuroprotective agent, delivery of exo-
genous BDNF is a good candidate for therapeutic treat-
ment of several CNS disorders.
Methods
FUS at 1.5 MHz with in-house microbubbles of an average
diameter of 4-5 mm was performed in transgenic AD
mice. Two transgenic mouse models, the PS/APP and J20,
were used, which are characterized by amyloid plaques
and cognitive deficits, respectively.
BDNF was injected following BBB opening. The BDNF
bioactivity was assessed quantitatively by immunohisto-
chemical detection of the pTrkB receptor and activated
pAkt, pMAPK, and pCREB in the hippocampal neurons.
Results and conclusions
BBB opening using FUS and microbubbles was found to
have similar characteristics and follows similar timelines
in AD mouse models as in wildtype mice. BDNF was
found to trigger molecular pathways with the pTrkB,
pMAPK and pCREB showing significant enhancement
compared to the contralateral hemisphere (no FUS).
Current efforts include demonstration of therapeutic
efficacy of BDNF delivery in AD mouse models. Targeting
of the hippocampus in non-human primates will also be
shown.
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